Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In a new announcement by Q32 Bio, positive topline results have been released from the 36-week analysis of Part B of the company’s phase 2a SIGNAL-AA trial, with investigational drug bempikibart showing clinically meaningful levels of hair regrowth and a favorable safety profile among those with severe or very severe 

Bempikibart met its primary endpoint, with a 35.3% mean reduction in SALT score and 40.0% of patients achieving SALT-20 at Week 36.

The therapy was generally well tolerated, with no treatment-related serious or Grade ≥3 adverse events reported.

Early durability was observed, with several patients maintaining or improving hair regrowth after stopping treatment, supporting further development.

The company’s release highlighted bempikibart’s design as a fully human monoclonal antibody targeting the interleukin-7 receptor alpha (IL-7Rα). Bempikibart was designed to modulate adaptive immune function via the inhibition of both IL-7 and thymic stromal lymphopoietin (TSLP) signaling.

"Alopecia areata is a complex, immune driven disease with limited therapeutic options,” Arash Mostaghimi, MD, MPA, MPH, associate professor of Dermatology and vice chair of Clinical Trials and Innovation for Brigham and Women's Hospital and Harvard Medical School, said in a statement.

“The robust efficacy data in a population that includes JAK inhibitor-experienced patients, combined with a differentiated safety profile, demonstrate the potential for bempikibart to be a first-line treatment for alopecia areata.”

What Was the SIGNAL-AA Part B Trial Design?

Enrollment in this open-label Part B analysis included 33 individuals showing baseline Severity of Alopecia Tool (SALT) scores ranging from 50 - 100. Additionally, they would have a current disease episode lasting no more than 4 years. The investigative team noted prior use by 36.4% of oral Janus kinase (JAK) inhibitors, indicating enrollment of a treatment-experienced population. According to the release, recruitment of subjects surpassed the company’s original target due to strong interest levels.

Participants received four weekly 200-mg loading doses followed by 200-mg subcutaneous injections every other week through Week 36. Investigators assessed changes in SALT scores as the primary efficacy endpoint, while additional analyses evaluated the proportion of patients reaching predefined thresholds of hair regrowth.

Bempikibart Demonstrates Clinically Meaningful Hair Regrowth at Week 36

At Week 36, patients in the modified intent-to-treat (mITT) population experienced a mean 35.3% reduction in SALT scores from baseline. Additionally, 40.0% of patients in the mITT analysis achieved a SALT-20 response, indicating at least 80% scalp hair coverage, while 44.0% met both SALT30 and SALT50 response criteria. Comparable response rates in the overall intent-to-treat population were 30.3% for SALT-20 and 33.3% for both SALT30 and SALT50. Responses were observed among patients with both severe and very severe disease at study entry.

Encouraging early findings highlighting durability after drug discontinuation were also identified by the investigative team. During the ongoing off-treatment follow-up period, several of the study’s subjects maintained or continued to improve their responses, including a single individual who reportedly attained full scalp hair regrowth.

What Is the Safety Profile of Bempikibart for Alopecia Areata?

Safety data were described as consistent with previous bempikibart research. The company highlighted a lack of treatment-related serious adverse events (AEs) or grade 3 or higher treatment-related AEs. Injection-site reactions were the most common treatment-emergent AE, with 36.3% of participants reporting such a reaction. However, the reactions were described as generally isolated, mild in their level of severity, and having resolved without intervention. They also appeared in only 4% of all of the study’s administered doses.

Q32 Bio also noted favorable pharmacodynamic, pharmacokinetic, and immunogenicity results. The loading-dose strategy attained steady-state drug concentrations approximately 10 weeks earlier than those observed in Part A, whereas anti-drug antibody development continued to be negligible.

Open-Label Extension Supports Durability of Response

In addition to the Part B results, the company shared findings resulting from the completed open-label SIGNAL-AA Part A extension study. Eight individuals, including prior drug responders, non-responders, and those on placebo, reinitiated the therapy after remaining off the medication for 26 - 55 weeks.

Long-term treatment continued to demonstrate a favorable safety profile, with patients who entered the extension having maintained hair growth generally sustaining or further improving their responses. According to Q32 Bio, these findings support the potential value of maintenance dosing.

Recruitment of participants in the ongoing Part B extension study was described as continuing. The company also described plans to present the full Part B dataset at a future medical conference. It intends to advance bempikibart into a registration-directed clinical program within the first half of 2027.

"For patients and prescribers seeking an effective and safe alternative to JAK inhibitors, these findings are encouraging and merit further clinical advancement,” Mostaghimi said in his statement.

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata. Q32 Bio Inc. July 13, 2026. 

https://www.prnewswire.com/news-releases/q32-bio-announces-positive-36-week-topline-results-from-part-b-of-the-signal-aa-clinical-trial-of-bempikibart-in-alopecia-areata-302823403.html

Articles

Q32 Bio reported positive 36-week topline phase 2a data for bempikibart, a fully human anti–IL-7Rα monoclonal antibody that inhibits IL-7 and TSLP signaling, in severe/very severe alopecia areata. In an open-label cohort (n=33; SALT 50–100; disease ≤4 years; 36.4% prior oral JAK exposure), treatment produced meaningful SALT improvements with notable SALT-20/30/50 response rates and signals of post-discontinuation durability. Safety was favorable, dominated by mild, infrequent injection-site reactions, with no treatment-related serious or grade ≥3 events.

Bempikibart use led to clinically meaningful SALT improvements among those with alopecia areata in the phase 2a SIGNAL-AA study at 36 weeks.

Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

SIGNAL-AA: Bempikibart Effective for Alopecia Areata at 36 Weeks

Morayo Adisa, MD, is a double board-certified dermatologist, dermatopathologist, and president of the Chicago Dermatological Society. She is also the medical director of Dermatology Physicians SC in Chicago and Kenilworth, Illinois.

Roxana Daneshjou, MD, PhD, is a board-certified dermatologist and physician-scientist who serves at Stanford University as an assistant professor in both the Department of Biomedical Data Science and the Department of Dermatology.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Skin of Color Savvy: Tech Check—AI, Telederm, and the Bias Question

Skin of Color Savvy: The Art and Science of Treating

, Morayo Adisa, MD, medical director of Dermatology Physicians SC in Chicago and Kenilworth, Illinois, sat down with Roxana Daneshjou, MD, PhD, assistant professor of biomedical data science and dermatology at Stanford University, to examine one of the most rapidly evolving topics in medicine: the intersection of artificial intelligence, 

, and equitable care for patients with skin of color.

AI systems can perpetuate existing healthcare disparities if trained on biased or nonrepresentative datasets.

Improving dermatology education and diversifying AI development are critical to achieving equitable care.

Teledermatology expands access but must address challenges including camera bias, digital access, and patient trust.

, featured a discussion exploring both the promise and limitations of artificial intelligence (AI) in dermatology, with Daneshjou emphasizing that while AI has the potential to improve healthcare delivery, it also risks perpetuating longstanding disparities if not developed and evaluated thoughtfully.

Daneshjou explained that many AI systems inherit biases already present within healthcare because they are trained on historical data that reflect existing inequities. She highlighted research demonstrating that algorithms have, in some cases, allocated healthcare resources inequitably by relying on spending data rather than true disease burden, inadvertently disadvantaging Black patients. Within dermatology specifically, she discussed her own work evaluating skin cancer detection algorithms, which found significantly poorer performance when identifying malignancies on darker skin tones compared with lighter skin.

A central theme of the episode was that AI cannot solve problems rooted in deficiencies within the healthcare system itself. Daneshjou noted that dermatology education has historically underrepresented skin of color in textbooks, educational resources, and training materials. As a result, clinicians may diagnose conditions later in patients with darker skin, limiting the availability of high-quality, early-stage clinical images needed to train more equitable AI systems. Improving AI performance, she argued, must begin with improving dermatology education and increasing representation across all aspects of clinical training.

The conversation also examined practical steps dermatologists can take to improve the future of AI. Daneshjou advocated for diversifying image datasets, ensuring broader representation among researchers and technology developers, and routinely evaluating algorithms for fairness before widespread implementation. She stressed that equity should be considered during the development process rather than only after products reach the market.

Adisa and Daneshjou also discussed the expanding role of teledermatology, acknowledging that virtual care has increased access for many patients while introducing new challenges. Although teledermatology can improve access for individuals with transportation or mobility limitations, Daneshjou cautioned that disparities persist through unequal internet access, language barriers, and differences in smartphone camera technology. She noted that camera systems have historically been calibrated using lighter skin tones, potentially reducing image quality and diagnostic accuracy for patients with darker skin during store-and-forward teledermatology encounters.

Patient trust emerged as another important focus. Daneshjou emphasized that patients should be informed whenever AI is incorporated into their care, whether through documentation tools, clinical decision support, or other technologies. She advocated for explicit patient consent surrounding AI use, particularly given evidence that current systems may not perform equally across diverse populations.

The discussion also touched on AI scribes, which have become increasingly common in clinical practice. Although available within her own institution, Daneshjou explained why she has chosen not to adopt the technology, citing concerns about patient privacy, inaccurate documentation, hallucinated clinical information, and the importance of personally crafting assessment and treatment plans as part of her own clinical reasoning process.

Looking toward the future, Daneshjou acknowledged that AI will almost certainly become more deeply integrated into healthcare but stressed that ongoing advocacy, rigorous evaluation, and greater diversity among developers will be essential to ensuring these technologies improve rather than worsen health disparities. She also identified textured hair and hair disorders as an area where AI research remains notably sparse, presenting an opportunity for future innovation in skin of color dermatology.

The episode concluded with a call for continued collaboration among clinicians, researchers, technology developers, and organizations such as the Skin of Color Society to ensure that advances in AI and digital health are guided by principles of equity, transparency, and representation, ultimately benefiting all patients regardless of skin tone.

To learn more about SOCS’s programs and initiatives, visit 

Editor’s note: This episode was summarized with the help of AI tools.

Kaundinya T, Kundu RV. Diversity of Skin Images in Medical Texts: Recommendations for Student Advocacy in Medical Education. J Med Educ Curric Dev. 2021 Jun 11;8:23821205211025855. doi: 10.1177/23821205211025855. PMID: 34179498; PMCID: PMC8202324.

Podcasts

In this podcast episode, 2 featured experts discuss AI, teledermatology, and strategies to reduce bias in skin of color dermatologic care.

Videos

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Chiadi Ndumele, MD, PhD, is the director of obesity and cardiometabolic research, director of the heart failure prevention program, and associate professor of medicine and epidemiology at Johns Hopkins University.

AHA, ACC Release First-Ever Cardiovascular-Kidney-Metabolic Syndrome Guidelines

The American Heart Association (AHA) and American College of Cardiology (ACC), among other organizations, have released the first-ever clinical guidelines for the diagnosis and management of cardiovascular-kidney-metabolic (CKM) syndrome.

These new guidelines expand on and fully replace the 2013 Guideline for the Management of 

 in Adults, aiming to provide concrete guidance for patients across the recently established CKM syndrome spectrum. The authors conducted a comprehensive literature search from October 2024 to April 2025, including data from MEDLINE, EMBASE, the Cochrane Library, and the Agency for Healthcare Research Quality, among others.

“These guidelines really build upon and reflect the fact that metabolic factors such as obesity and 

 and cardiovascular disease, and the fact that this is becoming the predominant form of cardiovascular risk in the population,” Chiadi Ndumele, MD, PhD, the director of obesity and cardiometabolic research, director of the heart failure prevention program, and associate professor of medicine and epidemiology at Johns Hopkins University, told 

 in an exclusive interview. “These guidelines equip us to better identify individuals with these challenges, to address the components of CKM syndrome holistically, and to think about what our care model needs to look like to support multi-system care for these patients.”

CKM syndrome is understood to originate as a result of excess or dysfunctional adipose tissue, which leads to inflammation in arteries, the kidney, and the heart, as well as insulin sensitivity. The disease is categorized into 4 separate stages, differentiated by clinical signs and risk factors, such as chronic inflammatory conditions, a family history of diabetes or kidney disease, and increased levels of elevated high-sensitivity C-reactive protein.

The guideline authors collected 10 of the top takeaways from the document, which include the following:

CKM syndrome staging is recommended for adolescents and adults to prevent progression, reduce cardiovascular events and loss of kidney function, and to promote regression through lifestyle changes

The Predicting Risk of Cardiovascular Disease EVENTS (PREVENT) equations are recommended to evaluate risk in patients over 10 and 30 years for 

atherosclerotic cardiovascular disease (ASCVD)

Metabolic risk factors and kidney function assessments should be conducted routinely among all adults, along with pre-HF, 

metabolic dysfunction-associated steatotic liver disease (MASLD)

Clinicians should routinely assess social determinants of health that may be linked with CKM syndrome development

Interdisciplinary care is recommended for patients with overlap among type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular disease – the clinicians also suggest a point person be included to coordinate efforts and facilitate care implementation

Treatment for overweight or obesity is recommended to assess risk related to excess adiposity, preventing CKM syndrome progression and promoting regression

Patients with T2D and cardiovascular disease or at risk of cardiovascular disease should receive cardioprotective antihyperglycemic guideline-directed medical therapy, including SGLT2i, GLP-1 RAs, or both

Clinicians should assess for CKD through eGFR and UACR to guide the use of kidney-protective agents

ASCVD management should emphasize CKM syndrome comorbidities like obesity, cardiovascular disease, and kidney function

CKM syndrome factors should be incorporated into HF care – nonsteroidal MRAs should be considered for those with T2D and CKD to prevent adverse cardiovascular events and loss of kidney function.

The guideline authors do note, however, that the document does not contain recommendations for blood pressure management, chronic coronary disease, dyslipidemia, HF, or peripheral artery disease. The document instead suggests that other AHA/ACC guidelines be consulted for these conditions.

“These guidelines will be very important for improving awareness among clinicians and among patients, and to start to adopt some of these evidence-based therapies earlier in a way that can really maximize care for individuals and keep us from waiting until the late stages when things are much more challenging to handle,” Ndumele said.

Editors’ Note: Ndumele reports no relevant disclosures.

Ndumele CE, Rodriguez F, Dixon DL, et al. 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online June 9, 2026. 

Ferdinand KC. An overview of cardiovascular-kidney-metabolic syndrome. Am J Manag Care. 2024;30(10 Suppl):S181-S188. 

Chiadi Ndumele, MD, PhD, breaks down the new guidelines and how they should be implemented in this sweeping document.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

Avapritinib 4-Year PIONEER Data: Sustained QoL Gains in ISM

Four-year data from the PIONEER trial show that avapritinib continues to improve emotional well-being and social functioning in patients with 

, extending beyond symptom and biomarker control alone, according to Thanai Pongdee, MD, of Mayo Clinic.

The analysis, presented at the European Academy of Allergy & Clinical Immunology (EAACI) 2026 Annual Meeting in Istanbul, followed 226 patients who initiated avapritinib 25 mg once daily across parts 1, 2, and 3 of the trial. The median treatment duration was 46.5 months, ranging from 0.7 to 67.2 months.

Emotional and Social Functioning Gains With Avapritinib 

Pongdee said the findings matter because chronic disease burden extends well beyond physical symptoms. Patients with ISM often withdraw from daily activities out of fear that a flare could occur without warning.

“We want patients to be able to function in their daily activities, whether it be work or social situations, because [the] disease, being chronic in nature, can significantly impact those kinds of activities and emotional well-being. Anything that can improve those aspects of a disease [is] as equally important as symptom control.”

Nearly half of patients reported less fear of an allergic reaction after long-term treatment, according to Pongdee. He said anaphylaxis-related anxiety is a major driver of quality-of-life impairment in ISM because reactions are frequently unpredictable.

"There's this constant worry that this could happen at any time," Pongdee said. He pointed to a previously published retrospective report suggesting avapritinib may reduce anaphylactic event risk, though he noted this remains under further investigation and was not a primary endpoint of PIONEER.

Sustained Quality of Life Improvement in ISM

Mean total symptom score on the ISM-Symptom Assessment Form (ISM-SAF TSS) and mean percentage change in Mastocytosis Quality of Life Questionnaire (MC-QoL) total score both showed continued improvement from baseline through 1 (-17.66 and -30.96, respectively) and 4 years (-17.66 and -35.41). These extended findings build on the placebo-controlled portion of PIONEER, in which avapritinib produced rapid, durable, and clinically meaningful improvements in ISM symptoms and quality of life compared with placebo through 24 weeks.

By 1 year, 31% of patients (n = 69) had reduced or discontinued use of ≥ 1 class of best supportive care (BSC) medication; by 3 years, that proportion rose to 52% (n = 118). The largest reductions were seen with cromolyn sodium (36.5%), anti-immunoglobulin E therapy (34.5%), and H1 (31.2%) and H2 (28.8%) antihistamines.

The safety profile of avapritinib with a median treatment duration of approximately 4 years remained consistent with what was previously reported in the placebo-controlled portion of the trial. Discontinuations due to treatment-related adverse events remained limited, occurring in 3% of patients (n = 6); grade ≥ 3 treatment-related adverse events stayed low.

The most frequently reported treatment-related adverse events were edema events, most of which were grade 1. Rates of cognitive adverse events and increased transaminases remained low and similar to placebo from the earlier controlled portion of the study, and no intracranial bleeds were observed. 1 death occurred during the study but was deemed unrelated to treatment, attributed to anaphylaxis in the context of atrial fibrillation in a patient with a prior history of both conditions.

“Decreasing [the anaphylaxis] risk…frees people…to do activities that we would consider pretty typical [but] would have otherwise been avoided,” Pongdee concluded. “Someone who never went out to eat, never went to a school reunion, [never attended] an employee picnic—things that a lot of us take for granted—can also enjoy those same activities.”

Reported disclosures for Pongdee include GlaxoSmithKline and Blueprint Medicines Corporation.

Broesby-Olsen S, Siebenhaar F, Oude Elberink H, et al. Mastocytosis Treated With Avapritinib: Updated 4-Year Results From The PIONEER Trial. Presented at European Academy of Allergy & Clinical Immunology (EAACI) 2026 Annual Meeting from June 12-15, 2026 in Istanbul, Türkiye.

Akin C. Long-Term PIONEER Data Reinforce Avapritinib’s Benefit–Risk Profile in ISM, with Cem Akin, MD. HCPLive. March 3, 2026. Accessed July 13, 2026. 

https://www.hcplive.com/view/long-term-pioneer-data-reinforce-avapritinib-benefit-risk-profile-ism-akin-md

4-year PIONEER data show avapritinib sustains symptom control and improves emotional well-being and social functioning in ISM, per Thanai Pongdee, MD. 

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Stevan Gonzalez, MD, MS, is the Director of Liver Transplantation at Baylor Scott and White All Saints Medical Center in Fort Worth, Texas. 

Closing Chronic Liver Disease Gaps Requires Earlier Detection, Community Outreach

Awareness, access, and community-driven screening may answer the unmet need of the underestimated rates of chronic liver disease in the US. Earlier detection is imperative to treat liver disease, so that clinicians can recommend lifestyle modifications, medications, and monitoring to halt damage and even reverse early-stage scarring.

Why Do Clinicians Need To Screen or Recognize Liver Disease Earlier?

“The liver is a vital organ capable of repairing itself,” Steven Gonzalez, MD, MS, Director of Liver Transplantation at Baylor Scott & White Health, said in an interview with 

Approaching Liver Health Through a Community Health Lens and Early Identification

 from the 2026 Liver Health Symposium, hosted by the Global Liver Institute. “ In many of these conditions [fatty liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease, and even viral hepatitis], even if a person does have evidence of advancing or progressive liver disease, you can actually avoid cirrhosis, and the liver can actually return to improved function and move further away from cirrhosis.”

What’s the Reality of Liver Disease in The US?

estimated 1.5% of the US’s adult population have chronic liver disease or cirrhosis, with mortality rates having nearly doubled since 1999. The most prominent underlying drivers of chronic liver disease include metabolic syndrome, chronic alcohol use, and viral hepatitis, particularly Hepatitis C.

More than 5 million people are living with chronic Hepatitis B or Hepatitis C.

About 42,340 new cases of liver cancer are diagnosed each year, with approximately 31,000 associated deaths.

Patient Populations Disproportionately Impacted by Liver Disease

Gonzalez emphasized that many chronic liver diseases disproportionately affect populations that may face barriers to accessing healthcare.

He pointed to hepatitis C as one example, noting that the disease disproportionately affects individuals who may not regularly seek medical care, including people experiencing homelessness, those who are incarcerated, and individuals with a history of injection drug use.

He added that MASLD can also be associated with social determinants of health, including food insecurity and limited access to resources that support healthy lifestyles and preventive care.

Gonzalez also highlighted the importance of targeted screening efforts. He noted that individuals from countries where hepatitis B is endemic should be screened for infection.

Other groups who may benefit from evaluation include people with diabetes, obesity, high cholesterol, high blood pressure, a family history of liver disease, or a history of excessive alcohol use.

“You need to really outreach to those communities in an effort to reduce the burden of liver disease in the US,” Gonzalez said.

Editor’s Note: Gonzalez reports relevant disclosures with Mallinckrodt Pharmaceuticals, Salix, AbbVie, Gilead, and others.

Alqahtani, S. A., Paik, J. M., Biswas, R., Arshad, T., Henry, L., & Younossi, Z. M. (2021). Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. 

(11), 1833–1847. https://doi.org/10.1002/hep4.1765

More than 40% of U.S. adults have liver disease, with higher risk among Hispanics, new study finds

https://www.vcuhealth.org/news/more-than-40-percent-of-us-adults-have-liver-disease-with-higher-risk-among-hispanics-new-study/

Stevan Gonzalez, MD, MS, explains patient characteristics and social determinants of health associated with chronic liver disease. 

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Strategic Alliance Partnership

Sara Lubitz, MD, outlines key research priorities, emerging PTH-axis therapies, and her expectation that hormone replacement will become the new standard of care in chronic hypoparathyroidism.



Video Series

The Future of Hypoparathyroidism Care: Research Priorities, Emerging Therapies, and Clinical Adoption of PTH Replacement

Sara Lubitz, MD, offers practical advice on transitioning appropriate patients to palopegteriparatide, including the dose-finding phase, laboratory monitoring, and considerations for women of childbearing potential.


Implementing Palopegteriparatide in Practice: Transition Protocols, Monitoring, and Reproductive Counseling

Sara Lubitz, MD, discusses guideline-based criteria for selecting patients for PTH therapy, treatment goals, and how palopegteriparatide may reduce renal complications and pill burden.

Who Benefits Most from PTH Therapy? Patient Selection, Goals of Care, and Renal Protection

Sara Lubitz, MD, explains how palopegteriparatide delivers sustained PTH1 receptor activation and reviews phase 3 data demonstrating durable biochemical control and improved renal and QoL outcomes.

Palopegteriparatide Mechanism and Phase 3 Outcomes in Chronic Hypoparathyroidism

Sara Lubitz, MD, reviews the modern landscape of chronic hypoparathyroidism, unmet needs with conventional calcium and vitamin D therapy, and the shift toward parathyroid hormone replacement.


Chronic Hypoparathyroidism Today: Unmet Needs, Conventional Therapy Limits, and the Shift to PTH Replacement

Kathleen Cook Suozzi, MD, is an associate professor of Dermatology and the director of Aesthetic Dermatology at the Yale School of Medicine. She specializes in Mohs micrographic surgery to treat skin cancer and uses lasers and photodynamic therapy to reverse sun damage.

As July is UV Safety Awareness Month, key tips for addressing sun damage, skin cancer signs, photoaging, and more are highlighted in this discussion.

What Are the Key Signs of UV Damage to Look For? With Kathleen Suozzi, MD

George Martin, MD, a dermatologist at the Dermatology and Laser Center of Maui and the co-founder of Scholars in Medicine and Maui Dermatology.

Martin discussed where hydroquinone still fits, why oral tranexamic acid remains underused, and how he decides when to escalate to procedural therapy.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Melasma Treatment Advances, With George Martin, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Elafibranor achieved 85% ALP normalization at week 52 in the phase 3b ELSPIRE trial for primary biliary cholangitis.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Elafibranor Achieves 85% ALP Normalization in Phase 3b ELSPIRE Trial for PBC

Andrew Adams MD, PhD, is Professor of Surgery and Chief of the Division of Transplantation at the University of Minnesota

Andrew Adams, MD, PhD, discusses Bestow Phase 2 data in tegoprubart compared to tacrolimus. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Tegoprubart Sustains Increased eGFR Longterm Compared to Tacrolimus

Parag Joshi, MD, is an assistant professor of medicine at UT Southwestern Medical Center and an adjunct assistant professor of medicine at Johns Hopkins School of Medicine.

Parag Joshi, MD, highlights CAC scoring’s value as a prognostic tool for lipid-lowering therapy.

Latest News

SIGNAL-AA: Bempikibart Effective for Alopecia Areata at 36 Weeks

Skin of Color Savvy: Tech Check—AI, Telederm, and the Bias Question

AHA, ACC Release First-Ever Cardiovascular-Kidney-Metabolic Syndrome Guidelines

Avapritinib 4-Year PIONEER Data: Sustained QoL Gains in ISM

Closing Chronic Liver Disease Gaps Requires Earlier Detection, Community Outreach